US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

VanEck Pharmaceutical ETF

109.44

-0.1600-0.15%

Post-market: 109.440.00000.00%19:30 EDT

Volume:128.97K

Turnover:14.12M

Market Cap:1.01B

PE:88.68

High:110.48

Open:110.00

Low:109.17

Close:109.60

52wk High:118.00

52wk Low:85.91

Shares:9.19M

Float Shares:9.19M

Volume Ratio:0.66

T/O Rate:1.40%

Dividend:2.17

Dividend Rate:1.98%

EPS(TTM):1.23

EPS(LYR):0.7765

ROE:--

ROA:--

PB:--

PE(LYR):140.94

Loading ...

Overview Company News Filings

Market Chatter: Novartis Shareholder Urges Board Changes After Trial Failures

MT Newswires Live

Novo Nordisk's Semaglutide Injection Gets Chinese Approval for MASH Treatment

MT Newswires Live

HSBC Adjusts Price Target on Eli Lilly and Co. to $940 From $850, Keeps Reduce Rating

MT Newswires Live

Novartis India Hits Record High After Recent Acquisition, Distribution Deal

Novo Nordisk Advances Oral Semaglutide Trial in Obesity: What Investors Should Watch

Novartis AG Falls Wednesday, Outperforms Market

Merck Price Target Raised to $161.00/Share from $127.00 by Leerink Partners

Novo Nordisk A/S Series B Stock Falls Wednesday

Dyne Therapeutics Myotonic Dystrophy Approach Remains Differentiated, RBC Says

MT Newswires Live

Novartis Shouldn't Rush to Cover Upcoming Patent Expirations

Abbvie Exec Says Strong Balance Sheet and Long Growth Runway Allow Company to Consider Both Early- and Late-Stage Business Development Opportunities - Conf Call

THOMSON REUTERS

Abbvie Exec Says Expects Approval of Subcutaneous Crohn's Disease Treatment in Q4 - Conf Call

THOMSON REUTERS

Shenzhen-Hong Kong-Guangzhou Innovation Hub Retains Global Crown for Second Consecutive Year

Henlius CEO Zhu Jun: Systematic Globalization Aims for Long-Term Gains, Innovative Drug Revenue Set to Surpass Biosimilars by 2030

Novo Nordisk Advances DKK 15 Billion Share Buyback, Holding 1% of Capital in Treasury Stock

Leerink Partners Adjusts Price Target on Merck & Co. to $161 From $127, Keeps Outperform Rating

MT Newswires Live

RBC Initiates Novartis at Sector Perform With CHF120 Price Target

MT Newswires Live

Merck & Co Inc : Leerink Partners Raises Target Price to $161 from $127

THOMSON REUTERS

Merck price target raised to $161 from $127 at Leerink

Novartis's Stock Selloff Looks Overdone

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnest.com/stock/PPH/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"PPH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PPH\",,,,,undefined,":{"symbol":"PPH","market":"US","secType":"STK","nameCN":"VanEck Pharmaceutical ETF","latestPrice":109.44,"timestamp":1789156800000,"preClose":109.6,"halted":0,"volume":128970,"hourTrading":{"tag":"盘后","latestPrice":109.44,"preClose":109.44,"latestTime":"19:30 EDT","volume":54,"amount":5913.48,"timestamp":1789169408034,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.001459854014598509,"floatShares":9188138,"shares":9188138,"eps":1.234146,"marketStatus":"Market Closed","change":-0.16,"latestTime":"09-11 16:00:00 EDT","open":110,"high":110.48,"low":109.17,"amount":14123255.014080001,"amplitude":0.011953,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":1.234146,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789372800000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":109.6,"sharesOutstanding":11938138,"nav":109.57845,"aum":995864089.78,"dividendRate":0.019823,"bidAskSpread":0.000358,"preHourTrading":{"tag":"盘前","latestPrice":110.8,"preClose":109.6,"latestTime":"09:03 EDT","volume":244,"amount":27058.2092,"timestamp":1789131791242,"change":1.2,"changeRate":0.010949,"amplitude":0.013777},"postHourTrading":{"tag":"盘后","latestPrice":109.44,"preClose":109.44,"latestTime":"19:30 EDT","volume":54,"amount":5913.48,"timestamp":1789169408034,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.6627168459003877,"impliedVol":0.2185,"impliedVolPercentile":0.7968},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PPH\",,,,,undefined,":{"symbol":"PPH","floatShares":9188138,"roa":"--","roe":"--","lyrEps":0.776475,"volumeRatio":0.6627168459003877,"shares":9188138,"dividePrice":2.1694,"high":110.48,"amplitude":0.011953,"preClose":109.6,"low":109.17,"week52Low":85.9086,"pbRate":"--","week52High":118,"institutionHeld":0,"latestPrice":109.44,"eps":1.234146,"divideRate":0.019823,"volume":128970,"delay":0,"ttmEps":1.234146,"open":110,"prevYearClose":103.17,"prevWeekClose":114.21,"prevMonthClose":113.08,"prevQuarterClose":109.35,"fiveDayClose":115.77,"twentyDayClose":111.52,"sixtyDayClose":105.09},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PPH\",params:#limit:5,,,undefined,":[{"date":"2026-07-01","symbol":"PPH","amount":0.6248,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-07-01","defaultRemindTime":1782912600000,"name":"VanEck Pharmaceutical ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-07-07","payableDate":"2026-07-01","currency":"USD","dateTimestamp":1782878400000,"payDate":"2026-07-07"},{"date":"2026-04-01","symbol":"PPH","amount":0.8441,"announcedDate":"2026-03-31","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-04-01","defaultRemindTime":1775050200000,"name":"VanEck Pharmaceutical ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-04-07","payableDate":"2026-04-01","currency":"USD","dateTimestamp":1775016000000,"payDate":"2026-04-07"},{"date":"2025-12-29","symbol":"PPH","amount":0.3106,"announcedDate":"2025-12-26","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-29","defaultRemindTime":1767018600000,"name":"VanEck Pharmaceutical ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-31","payableDate":"2025-12-29","currency":"USD","dateTimestamp":1766984400000,"payDate":"2025-12-31"},{"date":"2025-10-01","symbol":"PPH","amount":0.3931,"announcedDate":"2025-09-30","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-10-01","defaultRemindTime":1759325400000,"name":"VanEck Pharmaceutical ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-10-06","payableDate":"2025-10-01","currency":"USD","dateTimestamp":1759291200000,"payDate":"2025-10-06"},{"date":"2025-07-01","symbol":"PPH","amount":0.6069,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-07-01","defaultRemindTime":1751376600000,"name":"VanEck Pharmaceutical ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-07-07","payableDate":"2025-07-01","currency":"USD","dateTimestamp":1751342400000,"payDate":"2025-07-07"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PPH\",market:\"US\",,,undefined,":[{"executeDate":"2016-10-03","recordDate":"2016-10-05","paymentDate":"2016-10-07","value":0.2148,"currency":"USD"},{"executeDate":"2016-12-28","recordDate":"2016-12-30","paymentDate":"2017-01-04","value":0.1449,"currency":"USD"},{"executeDate":"2017-04-03","recordDate":"2017-04-05","paymentDate":"2017-04-07","value":0.4651,"currency":"USD"},{"executeDate":"2017-07-03","recordDate":"2017-07-06","paymentDate":"2017-07-10","value":0.304,"currency":"USD"},{"executeDate":"2017-10-02","recordDate":"2017-10-03","paymentDate":"2017-10-06","value":0.221,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PPH\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PPH\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2666598612","title":"Market Chatter: Novartis Shareholder Urges Board Changes After Trial Failures","url":"https://stock-news.laohu8.com/highlight/detail?id=2666598612","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666598612?lang=en_us&edition=fundamental","pubTime":"2026-09-10 19:47","pubTimestamp":1789040824,"startTime":"0","endTime":"0","summary":"Novartis  shareholder Artisan Partners called for changes to the Swiss drugmaker's board following two consecutive drug trial setbacks that sent shares tumbling, Reuters reported Thursday, citing an interview with Artisan managing director David Samra.Novartis needs stronger oversight of acquisitions, citing the $12 billion Avidity deal and the 2024 MorphoSys acquisition, which was later written down, Samra told ReutersSamra questioned the board's acquisition oversight, while Novartis reaffirmed its unchanged guidance and focus on disciplined capital allocation and shareholder returns, Reuters added.Novartis shares were up 1.7% in premarket activity.Novartis did not immediately respond to MT Newswires' request for comment.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NVS","BK4585","IE00BJT1NW94.SGD","IE0002141913.USD","IE00BJJMRZ35.SGD","IE00B4R5TH58.HKD","LU0208291251.USD","BK4588","LU0070302665.USD","IE00BFTCPJ56.SGD","LU0320765489.SGD","BK4007","IE00B2B36J28.USD","BK4578","BK4532","PPH","MEDX","IE0009355771.USD","LU0211331839.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666453561","title":"Novo Nordisk's Semaglutide Injection Gets Chinese Approval for MASH Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2666453561","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666453561?lang=en_us&edition=fundamental","pubTime":"2026-09-10 17:35","pubTimestamp":1789032909,"startTime":"0","endTime":"0","summary":"Novo Nordisk  said Thursday that China's National Medical Products Administration has approved its Semaglutide injection to treat metabolic-associated steatohepatitis, according to a Google translation of its Chinese statement.The company said that approval was based on results from its ESSENCE trial, which showed that 63% of patients treated with Semaglutide achieved MASH remission and no worsening of liver fibrosis, compared to 34% in the placebo group.Novo also said that 37% of patients treated with semaglutide demonstrated improvements in liver fibrosis and no worsening of MASH, compared to 22% in the placebo group.Treatment with the Smegglutide injection relieved liver inflammation in some patients and improved the \"scar\" tissue formed after long-term liver damage, the company added.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1093756325.SGD","NVOC","LU0154236417.USD","BK4007","BK4585","LU1093756168.USD","THNR","NVOH","NVO","IE00BKVL7J92.USD","NVOX","OZEM","IE00BZ1G4Q59.USD","BK4588","PPH","BK4532","BK4599"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666561456","title":"HSBC Adjusts Price Target on Eli Lilly and Co. to $940 From $850, Keeps Reduce Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2666561456","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666561456?lang=en_us&edition=fundamental","pubTime":"2026-09-10 17:34","pubTimestamp":1789032857,"startTime":"0","endTime":"0","summary":"Eli Lilly and Company (LLY) has an average rating of overweight and mean price target of $1,352.49, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["FTXH","LLY","LU0289739699.SGD","LU1548497426.USD","LU0006306889.USD","WDNA","LU2896262040.SGD","LU1291159041.SGD","LU2552382132.HKD","LU2491049909.HKD","BK4599","SGXZ99366536.SGD","LU2063271972.USD","IYH","LU2324357040.USD","LU0097036916.USD","LU2211815571.USD","LU0466842654.USD","GB00BDT5M118.USD","LU2468319806.SGD","LU1551013425.SGD","LU2360106947.USD","BK4585","GDOC","LU2471134879.HKD","TRUH","LU2237443465.HKD","LLYX","LU0323591593.USD","LU0820561909.HKD","LU2237443549.SGD","LU2168564065.EUR","LU2361044865.SGD","LU1868836591.USD","LU0225283273.USD","IE00BJJMRZ35.SGD","LU1280957306.USD","LU2602419157.SGD","SG9999014880.SGD","LU2750360997.AUD","BK4534","IE0005OL40V9.USD","LU2168564149.EUR","LU2112291526.USD","LU2750360641.GBP","OZEM","LU0823416689.USD","LU1023059063.AUD","LU2746668461.USD","IE00BJT1NW94.SGD","LU2108987350.USD","LU2756315664.SGD","TMED","SG9999018857.SGD","SG9999015978.USD","IE00BK4W5L77.USD","LU0353189763.USD","LU2756315318.SGD","LU2168563687.JPY","LU2471134523.USD","IHE","IE00BWXC8680.SGD","LU1323610961.USD","LU0385154629.USD","LU1057294990.SGD","SG9999018865.SGD","VHT","LU0354030438.USD","LU0094547139.USD","PJP","IE00BFSS8Q28.SGD","AGNG","LU1814569148.SGD","IE00BN29S564.USD","SGXZ51526630.SGD","RXL","LU1093756325.SGD","IE0002141913.USD","LU0234572021.USD","ILDR","LU1712237335.SGD","LU1629891620.HKD","LU0256863811.USD","LU1127390331.HKD","LU0820562030.AUD","LU0882574055.USD","LU1061106388.HKD","IE0004445015.USD","LU0133085943.USD","LU0109391861.USD","LU2023250330.USD","SG9999001176.USD","LU2236285917.USD","LU0079474960.USD","LU0640476718.USD","LU0096364046.USD","LU2168564495.EUR","IE00B2B36J28.USD","LU0820561818.USD","THNR","IE00B4R5TH58.HKD","LU1868837300.USD","LU2023251221.USD","SG9999014898.SGD","LU2552382215.SGD","LU1804176565.USD","LU1979441026.SGD","LU1093756168.USD","IE0004445239.USD","LU2461242641.AUD","LU2456880835.USD","LU1232071149.USD","LU0787776722.HKD","LU0238689110.USD","LU0122379950.USD","BK4533","LU0708995401.HKD","LU1988902786.USD","LU2417539215.USD","IE00B4JS1V06.HKD","IE00B775H168.HKD","LU0964807845.USD","LU1974910355.USD","XLV","LU1064131342.USD","IE0001KFT4U8.USD","LU1366192091.USD","LU0203201768.USD","SG9999001176.SGD","IE00BFSS7M15.SGD","IXJ","SG9999015986.USD","LU1623119135.USD","LU2237443978.SGD","IE00BKPKM429.USD","LU1551013342.USD","SGXZ31699556.SGD","LU0174119429.USD","LU2168564222.USD","IE00B1BXHZ80.USD","LU0256863902.USD","LU0432979614.USD","LU2111349929.HKD","LU2237443382.USD","ELIS","LU0786609619.USD","IE0009355771.USD","LU0345770993.USD","LU0456855351.SGD","MEDX","LU2237443622.USD","LU2471134952.CNY","LU1267930730.SGD","LLYZ","LU0106261372.USD","LU0672654240.SGD","LU1917777945.USD","LU0471298694.HKD","LU2265009873.SGD","LU2462591350.SGD","LU0471298777.SGD","LU2462157665.USD","LU0882574139.USD","LU2237443895.HKD","LU2357305700.SGD","SG9999014914.USD","LU0203202063.USD","IE00BFTCPJ56.SGD","BK4007","LU0198837287.USD","SG9999017495.SGD","BK4516","LU0345770308.USD","LU2089283258.USD","BK4588","LU0114720955.EUR","LU0689472784.USD","LU2087625088.SGD","LLII","LU2023250504.SGD","LU0320765992.SGD","LU2237438978.USD","LU0320765059.SGD","LU0158827781.USD","LU2491050071.SGD","LU0266013472.USD","LU2213496289.HKD","LU0058720904.USD","IE00B1XK9C88.USD","LU1868836914.USD","BK4581","IE00BKDWB100.SGD","IE00BJJMRY28.SGD","LU1989771016.USD","LU2028103732.USD","JDOC","LU0354030511.USD","LU2552382058.USD","SG9999015952.SGD","IE00BK4W5M84.HKD","LU1720051108.HKD","LU0823434583.USD","LU0889565916.HKD","SGXZ81514606.USD","SG9999014906.USD","LU1868836757.USD","IE00B7KXQ091.USD","LU1145028129.USD","LU0316494557.USD","MHIP","LU2361044949.HKD","MEDI","LU0823434740.USD","LU1983299246.USD","LU1720051017.SGD","LU0353189680.USD","LU0683600562.USD","PPH","SG9999015945.SGD","LU0943347566.SGD","IE00BJLML261.HKD","LU2106854487.HKD","LU0158827948.USD","LU2089284900.SGD","LU1069344957.HKD","LU2491050154.USD","LU0417517546.SGD","CANC","LU1691799644.USD","LU2271345857.HKD","SG9999013999.USD","SGXZ57979304.SGD","CURE","LU1035775433.USD","LU2746668974.SGD","LU2264538146.SGD","LU0210536198.USD","LU2089984988.USD","LU2361045086.USD","LU2471134796.USD","FHLC","IE00BJJMRX11.SGD","ELIL","HRTS","LU0061475181.USD","LU0109394709.USD","LU1868837136.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666655750","title":"Novartis India Hits Record High After Recent Acquisition, Distribution Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2666655750","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666655750?lang=en_us&edition=fundamental","pubTime":"2026-09-10 13:29","pubTimestamp":1789018142,"startTime":"0","endTime":"0","summary":"BUZZ-Novartis India hits record high after recent acquisition, distribution deal** Pharma co Novartis India'sNOIN.BOshares rise 18% to 2,580 rupees, hitting an all-time high** Stock has gained in six of last seven trading sessions** Gains come after co on Tuesday said it entered into an exclusive promotion and distribution agreement with Novartis Healthcare to market its retina portfolio in India** On Monday, Novartis India said that it would acquire the Minipress brand and related IP from PfizerPFE.Nfor about 12.5 billion rupees ** NOIN holds trailing 12-month PE of 55.26 vs industry median of 23.98","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260910:nL4N4520C5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B4R5TH58.HKD","LU2596442595.SGD","BK4568","SG9999013999.USD","LU0868494617.USD","IE00BLSP4239.USD","BK4599","BK4007","IE0002141913.USD","BK4532","IE0009355771.USD","LU0208291251.USD","LU1883839398.USD","MEDX","SG9999001176.SGD","LU0306806265.USD","LU0058720904.USD","IE00BBT3K403.USD","LU0321505439.SGD","IE00BJT1NW94.SGD","LU0289739699.SGD","LU1066051498.USD","SG9999003800.SGD","LU1894683348.USD","IE00BJJMRZ35.SGD","BK4534","LU1894683264.USD","BK4550","NVS","BK4581","SG9999001176.USD","LU0234572021.USD","LU0306807586.USD","IE00B19Z3B42.SGD","BK4578","IE00B3T34201.USD","LU1057294990.SGD","LU1023059063.AUD","LU0985481810.HKD","IE0002270589.USD","IE00B2B36J28.USD","SG9999002232.USD","LU0321505868.SGD","LU0170899867.USD","SG9999002224.SGD","SGXZ57979304.SGD","LU0225771236.USD","LU0225284248.USD","IE00BFTCPJ56.SGD","SG9999011175.SGD","IE00BLSP4452.SGD","LU0211331839.USD","IE000M9KFDE8.USD","BK4585","IE00B19Z3581.USD","LU0456855351.SGD","LU1066053197.SGD","LU0122379950.USD","PFE","BK4588","BK4533","LU0320765489.SGD","LU0070302665.USD","BK4592","PPH","OZEM"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2666534630","title":"Novo Nordisk Advances Oral Semaglutide Trial in Obesity: What Investors Should Watch","url":"https://stock-news.laohu8.com/highlight/detail?id=2666534630","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666534630?lang=en_us&edition=fundamental","pubTime":"2026-09-10 00:31","pubTimestamp":1788971502,"startTime":"0","endTime":"0","summary":"Novo Nordisk ($NVO) announced an update on their ongoing clinical study. Novo Nordisk’s new Phase 3 trial, “Efficacy and Safety of Once Daily Oral ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/novo-nordisk-advances-oral-semaglutide-trial-in-obesity-what-investors-should-watch?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/novo-nordisk-advances-oral-semaglutide-trial-in-obesity-what-investors-should-watch?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4532","BK4599","IE00BKVL7J92.USD","NVOC","OZEM","THNR","BK4585","BK4588","BK4007","NVOH","PPH","LU0154236417.USD","NVO","LU1093756325.SGD","IE00BZ1G4Q59.USD","NVOX","LU1093756168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666531005","title":"Novartis AG Falls Wednesday, Outperforms Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2666531005","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666531005?lang=en_us&edition=fundamental","pubTime":"2026-09-10 00:15","pubTimestamp":1788970500,"startTime":"0","endTime":"0","summary":"This article was automatically generated using Dow Jones technology.Shares of Novartis AG  slipped 0.1% to CHF111.66 Wednesday on what proved to be an overall unfavorable trading session for the stock market, with the Swiss Market Index SMI Index  falling 1.8% to 13,804.70.Novartis AG closed CHF21.02 below its 52-week high of CHF132.68, which the company achieved on September 3, 2026.Trading volume was 4,314,570, compared to the 50-day average trading volume of 2,451,167.Data source: Dow Jones Market Data, FactSet","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IE0002141913.USD","BK4532","IE00BJJMRZ35.SGD","NVS","BK4588","IE00B2B36J28.USD","IE00B4R5TH58.HKD","PPH","BK4578","MEDX","IE00BFTCPJ56.SGD","LU0208291251.USD","LU0320765489.SGD","IE00BJT1NW94.SGD","LU0070302665.USD","BK4007","IE0009355771.USD","LU0211331839.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666531778","title":"Merck Price Target Raised to $161.00/Share from $127.00 by Leerink Partners","url":"https://stock-news.laohu8.com/highlight/detail?id=2666531778","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666531778?lang=en_us&edition=fundamental","pubTime":"2026-09-10 00:13","pubTimestamp":1788970380,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MRK/analyst-ratings","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0130102774.USD","LU0211331839.USD","IE00BJJMRZ35.SGD","LU1061106388.HKD","LU1989772840.SGD","LU1057294990.SGD","LU2468319806.SGD","IYH","LU1571399168.USD","LU1989771016.USD","LU1585245621.USD","LU0058720904.USD","BMED","LU0208291251.USD","LU1035773651.USD","LU1037948897.HKD","SG9999001176.SGD","SG9999015358.SGD","LU0868494617.USD","IE00BFTCPJ56.SGD","LU0648001328.SGD","IE000M9KFDE8.USD","LU2106854487.HKD","LU1066051225.USD","LU2125909247.SGD","BK4585","LU0965508806.USD","LU0289739699.SGD","PAWZ","LU2023250843.SGD","IE00BLSP4452.SGD","BK4516","GDOC","LU0234572021.USD","LU0477156953.USD","MRK","HRTS","LU1201861249.SGD","LU2491050071.SGD","BK4588","LU2433249047.HKD","SG9999002232.USD","LU1974910355.USD","LU1032466523.USD","LU0203345920.USD","LU0124676726.USD","LU1430594728.SGD","VHT","JDOC","LU0265550946.USD","LU1066051498.USD","IE00B1BXHZ80.USD","LU2125909593.SGD","LU1066051811.HKD","BK4559","BK4550","LU2324357040.USD","RXL","LU0823416689.USD","LU1116320901.HKD","IE0009355771.USD","LU0965509010.AUD","LU0098860793.USD","LU1929549753.HKD","LU2461242641.AUD","SG9999001176.USD","SG9999002224.SGD","LU0070302665.USD","IE00BN8TJ469.HKD","LU0432979614.USD","LU1941712264.USD","LU2125154935.USD","LU2360032135.SGD","IE00BJT1NW94.SGD","IE00B4R5TH58.HKD","IE00BSNM7G36.USD","LU1983299246.USD","LU2125154778.USD","LU1917777945.USD","BK4007","LU1037948541.HKD","LU2089984988.USD","LU0689626769.HKD","LU1941712348.USD","LU0320765489.SGD","LU0965509101.SGD","LU0106261372.USD","SG9999001440.SGD","SG9999014567.USD","LU1093756168.USD","FHLC","LU0861579265.USD","LU0238689110.USD","LU2361045086.USD","LU0266013472.USD","IE00BBT3K403.USD","LU0985320562.USD","XLV","LU2361044865.SGD","LU0320765646.SGD","LU1069347547.HKD","LU0122379950.USD","LU1116320737.USD","LU2112291526.USD","SG9999013999.USD","LU0006306889.USD","IXJ","LU0265550359.USD","LU1989772923.USD","IE00B2B36J28.USD","LU1934455277.USD","IHE","LU2491050154.USD","LU0868494708.USD","LU1934455863.HKD","BK4533","LU0130517989.USD","TRUH","IE00BLSP4239.USD","LU1291159041.SGD","SG9999014559.SGD","LU1934455194.USD","SGXZ57979304.SGD","SG9999014575.USD","LU1066053197.SGD","LU0203347892.USD","LU1162221912.USD","LU2357627491.SGD","LU1093756325.SGD","LU1923622614.USD","PPH","IE0002141913.USD","SG9999015341.SGD","FTXH","BK4534","SG9999014542.SGD","LU0965509283.SGD","LU2491049909.HKD","LU0942090050.USD","LU1699723380.USD","LU0859254822.USD","LU0980610538.SGD","LU2023250504.SGD","LU1023059063.AUD","LU2361044949.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666294531","title":"Novo Nordisk A/S Series B Stock Falls Wednesday","url":"https://stock-news.laohu8.com/highlight/detail?id=2666294531","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666294531?lang=en_us&edition=fundamental","pubTime":"2026-09-10 00:02","pubTimestamp":1788969720,"startTime":"0","endTime":"0","summary":"This article was automatically generated using Dow Jones technology.Shares of Novo Nordisk A/S Series B dropped 1.1% to DKK288.90 Wednesday on what proved to be an overall unfavorable trading session for the stock market, with the OMX Nordic 40 Index falling 1.1% to 2,686.31.This was the stock's second consecutive day of losses.The company closed DKK121.05 short of its 52-week high of DKK409.95, which the company reached on January 23, 2026.Trading volume was 4,429,973, compared to the 50-day average trading volume of 4,078,075.Data source: Dow Jones Market Data, FactSet","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1093756325.SGD","NVO","BK4532","NVOC","IE00BZ1G4Q59.USD","LU0154236417.USD","OZEM","BK4588","BK4007","IE00BKVL7J92.USD","LU1093756168.USD","NVOH","BK4599","NVOX","THNR","BK4585","PPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666539005","title":"Dyne Therapeutics Myotonic Dystrophy Approach Remains Differentiated, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2666539005","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666539005?lang=en_us&edition=fundamental","pubTime":"2026-09-09 23:10","pubTimestamp":1788966641,"startTime":"0","endTime":"0","summary":"Dyne Therapeutics  investment thesis remains intact despite a setback for Novartis  in a phase 3 trial for myotonic dystrophy type 1, as differences in drug targeting, payload and clinical strategy could lead to different outcomes, RBC Capital Markets said in a Tuesday note.According to the analysts, Dyne's approach uses an antibody fragment rather than a full-length antibody, an antisense oligonucleotide rather than small interfering RNA, and a six month primary endpoint versus 12 months for Novartis' trial.RBC said Dyne remains confident in its phase 3 study, with data expected in Q1 2027.Dyne is also running a confirmatory phase 3 study using the five times sit-to-stand test as its primary endpoint, providing a second opportunity to achieve statistical significance, the note said.The analysts also see a potential catalyst in Dyne's DMD51 program, with a US Food and Drug Administration decision expected Jan. 21, 2027.RBC maintained its outperform rating on Dyne Therapeutics and lower","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0208291251.USD","IE00BFTCPJ56.SGD","NVS","BK4139","IE0002141913.USD","LU0211331839.USD","PPH","BK4585","LU0070302665.USD","BK4532","IE00BJT1NW94.SGD","IE00BJJMRZ35.SGD","MEDX","BK4007","BK4505","BK4588","IE00B2B36J28.USD","LU0320765489.SGD","DYN","IE00B4R5TH58.HKD","BK4578","IE0009355771.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666253906","title":"Novartis Shouldn't Rush to Cover Upcoming Patent Expirations","url":"https://stock-news.laohu8.com/highlight/detail?id=2666253906","media":"Dow Jones","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666253906?lang=en_us&edition=fundamental","pubTime":"2026-09-09 23:07","pubTimestamp":1788966420,"startTime":"0","endTime":"0","summary":"1507 GMT - Recent clinical-trial setbacks mean Novartis needs to be near-flawless in bringing the rest of its pipeline to the market or look for deals, but the Swiss drugmaker shouldn't rush it, RBC Capital Markets analysts say in a research note. \"Shares have pulled back from all-time highs, but we see no urgency to act,\" the analysts say. The failures of cardiovascular and neuromuscular drugs pelacarsen and del-desiran raise the bar for Novartis's pipeline, given that these were two important candidates to offset sales lost to upcoming patent expirations, they add. RBC starts coverage on the stock with a sector perform recommendation and a target price of 120 Swiss francs. Shares fall 0.3% to 111.44 francs.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0211331839.USD","IE00BJJMRZ35.SGD","BK4578","LU0320765489.SGD","NVS","BK4532","LU0208291251.USD","IE00BFTCPJ56.SGD","PPH","MEDX","IE0002141913.USD","IE0009355771.USD","LU0070302665.USD","BK4585","IE00BJT1NW94.SGD","IE00B2B36J28.USD","IE00B4R5TH58.HKD","BK4588","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666539473","title":"Abbvie Exec Says Strong Balance Sheet and Long Growth Runway Allow Company to Consider Both Early- and Late-Stage Business Development Opportunities - Conf Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2666539473","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666539473?lang=en_us&edition=fundamental","pubTime":"2026-09-09 22:25","pubTimestamp":1788963943,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nFWN45113M:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SG9999011175.SGD","LU1989772840.SGD","LU0170899867.USD","IE000MB6IJN5.SGD","SG9999003800.SGD","LU0912757837.SGD","LU0689626769.HKD","IE00B19Z3B42.SGD","PPH","LU1934455277.USD","IE00BLSP4239.USD","LU0965509010.AUD","IE00BLSP4452.SGD","AGNG","FHLC","IXJ","BK4566","FTXH","LU0114720955.EUR","LU0882574055.USD","LU0417517546.SGD","LU0158827948.USD","LU0289961442.SGD","IYH","PJP","LU0553294199.USD","LU1037948541.HKD","LU1732799900.SGD","MEDX","TRUH","LU2112291526.USD","LU1236620834.HKD","LU0234572021.USD","LU0708994859.HKD","LU1267930490.SGD","GLAM","LU2089984988.USD","JDOC","LU2089284900.SGD","RXL","LU0029864427.USD","SG9999015986.USD","LU2237443978.SGD","LU0122379950.USD","XLV","VHT","ABBV","LU0738911758.USD","LU0289739699.SGD","LU0456855351.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666539343","title":"Abbvie Exec Says Expects Approval of Subcutaneous Crohn's Disease Treatment in Q4 - Conf Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2666539343","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666539343?lang=en_us&edition=fundamental","pubTime":"2026-09-09 22:25","pubTimestamp":1788963943,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nFWN45113M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SG9999015986.USD","LU2237443895.HKD","BK4566","LU1923622614.USD","VHT","IE00BFTCPJ56.SGD","LU1003077747.HKD","IE00BDGV0183.EUR","ABBV","LU1585245621.USD","IE00BLSP4452.SGD","LU0310799852.SGD","LU0122379950.USD","LU0198837287.USD","LU0689472784.USD","LU0820561818.USD","IE00BVYPNW00.USD","IE000BZT7R73.USD","GLAM","IE00B19Z3581.USD","LU1037948541.HKD","IE00B19Z3B42.SGD","FTXH","LU0098860793.USD","MEDX","IXJ","LU1093756325.SGD","LU1236620834.HKD","IE0000B7K699.USD","LU2129689431.USD","TRUH","LU0726765562.USD","PJP","LU0128525929.USD","LU0965508806.USD","LU2347655073.USD","LU2125909593.SGD","LU1929549753.HKD","JDOC","LU0882574055.USD","IE00BJJMRZ35.SGD","PPH","IYH","RXL","LU0472753341.HKD","XLV","LU0912757837.SGD","IE0002270589.USD","FHLC","AGNG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160778799","title":"Shenzhen-Hong Kong-Guangzhou Innovation Hub Retains Global Crown for Second Consecutive Year","url":"https://stock-news.laohu8.com/highlight/detail?id=1160778799","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1160778799?lang=en_us&edition=fundamental","pubTime":"2026-09-09 21:41","pubTimestamp":1788961312,"startTime":"0","endTime":"0","summary":"The World Intellectual Property Organization (WIPO) released its 2026 Global Innovation Index report on September 8, unveiling the top 100 science and technology innovation clusters worldwide....","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PPH","PATN","NXTI","TISC","ITAN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107437767","title":"Henlius CEO Zhu Jun: Systematic Globalization Aims for Long-Term Gains, Innovative Drug Revenue Set to Surpass Biosimilars by 2030","url":"https://stock-news.laohu8.com/highlight/detail?id=1107437767","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107437767?lang=en_us&edition=fundamental","pubTime":"2026-09-09 21:11","pubTimestamp":1788959461,"startTime":"0","endTime":"0","summary":"During the 2026 Yabuli Forum Summer Annual Meeting, Henlius (02696.HK) Executive Director and CEO Dr. Zhu Jun outlined the company's \"systematic globalization\" strategy in an in-depth conversation,...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","HK0000306701.USD","BK1574","MEDX","HK0000320264.USD","LNGR","06978","BK4585","LU2272731782.SGD","XPH","IBB","LU1992135399.USD","BK4588","LU2322448791.USD","02696","HK0000165453.HKD","IBBQ","LU2272731865.HKD","LU2322448957.HKD","LU2272731600.USD","PPH","LU2473716301.USD","IE00B5TLWC47.USD","159992","LU1992135472.HKD","HK0000320223.HKD","HK0000306685.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666587338","title":"Novo Nordisk Advances DKK 15 Billion Share Buyback, Holding 1% of Capital in Treasury Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2666587338","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666587338?lang=en_us&edition=fundamental","pubTime":"2026-09-09 18:49","pubTimestamp":1788950956,"startTime":"0","endTime":"0","summary":"An announcement from Novo Nordisk ( ($NVO) ) is now available. Novo Nordisk has continued executing its previously announced share repurchase progr...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/novo-nordisk-advances-dkk-15-billion-share-buyback-holding-1-of-capital-in-treasury-stock?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/novo-nordisk-advances-dkk-15-billion-share-buyback-holding-1-of-capital-in-treasury-stock?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1093756325.SGD","NVOC","LU0154236417.USD","BK4007","BK4585","LU1093756168.USD","THNR","NVOH","NVO","IE00BKVL7J92.USD","NVOX","OZEM","IE00BZ1G4Q59.USD","BK4588","PPH","BK4532","BK4599"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666821375","title":"Leerink Partners Adjusts Price Target on Merck & Co. to $161 From $127, Keeps Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2666821375","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666821375?lang=en_us&edition=fundamental","pubTime":"2026-09-09 18:47","pubTimestamp":1788950858,"startTime":"0","endTime":"0","summary":"Merck & Co. (MRK) has an average rating of overweight and mean price target of $150.40, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1201861249.SGD","IE00BLSP4452.SGD","LU1093756325.SGD","LU0203347892.USD","BK4585","LU1941712264.USD","LU0861579265.USD","LU0266013472.USD","PAWZ","LU1162221912.USD","IE000M9KFDE8.USD","LU0648001328.SGD","IYH","IE00B2B36J28.USD","LU0234572021.USD","LU1989772923.USD","LU2324357040.USD","TRUH","LU2491049909.HKD","LU2023250843.SGD","LU1934455277.USD","LU0265550359.USD","LU2361044949.HKD","SG9999014567.USD","LU0965509283.SGD","LU0208291251.USD","LU0058720904.USD","LU0432979614.USD","LU0980610538.SGD","FHLC","LU2125154935.USD","BK4516","SG9999014559.SGD","LU2461242641.AUD","LU2023250504.SGD","LU1929549753.HKD","LU2112291526.USD","LU0985320562.USD","LU0823416689.USD","LU1032466523.USD","LU1934455194.USD","SG9999001440.SGD","LU1430594728.SGD","LU1066051811.HKD","LU1974910355.USD","LU2468319806.SGD","SG9999001176.SGD","BMED","LU1983299246.USD","IE0009355771.USD","IE00BN8TJ469.HKD","LU0859254822.USD","LU2361044865.SGD","LU0965509101.SGD","IE00BFTCPJ56.SGD","IE00B1BXHZ80.USD","LU0070302665.USD","LU0868494617.USD","HRTS","IHE","SG9999013999.USD","LU2125909593.SGD","VHT","SG9999014575.USD","LU1116320737.USD","LU1116320901.HKD","LU0689626769.HKD","LU0203345920.USD","BK4588","FTXH","LU0320765646.SGD","RXL","LU0868494708.USD","LU0320765489.SGD","SG9999002224.SGD","LU1699723380.USD","BK4007","LU1066051498.USD","LU1941712348.USD","LU2125909247.SGD","LU1093756168.USD","LU2106854487.HKD","IE0002141913.USD","LU2433249047.HKD","LU2361045086.USD","LU0942090050.USD","LU0124676726.USD","LU1291159041.SGD","LU0130517989.USD","LU2089984988.USD","LU0122379950.USD","LU2491050154.USD","IE00BLSP4239.USD","SGXZ57979304.SGD","LU0238689110.USD","SG9999001176.USD","LU1037948541.HKD","LU0477156953.USD","IE00BSNM7G36.USD","IE00BJJMRZ35.SGD","MRK","LU1989771016.USD","LU1023059063.AUD","LU1923622614.USD","LU1057294990.SGD","IE00B4R5TH58.HKD","LU2357627491.SGD","LU2360032135.SGD","SG9999015358.SGD","LU1066053197.SGD","LU1934455863.HKD","GDOC","SG9999002232.USD","SG9999014542.SGD","LU0965509010.AUD","LU1917777945.USD","LU2125154778.USD","BK4534","LU1069347547.HKD","LU0006306889.USD","BK4533","LU0130102774.USD","LU0211331839.USD","IXJ","BK4550","LU2491050071.SGD","LU0265550946.USD","JDOC","LU1035773651.USD","LU1066051225.USD","LU0289739699.SGD","LU1037948897.HKD","LU1585245621.USD","LU0098860793.USD","LU1061106388.HKD","PPH","LU0106261372.USD","BK4559","IE00BJT1NW94.SGD","LU1989772840.SGD","SG9999015341.SGD","XLV","LU1571399168.USD","IE00BBT3K403.USD","LU0965508806.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666847965","title":"RBC Initiates Novartis at Sector Perform With CHF120 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2666847965","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666847965?lang=en_us&edition=fundamental","pubTime":"2026-09-09 18:29","pubTimestamp":1788949792,"startTime":"0","endTime":"0","summary":"Novartis's (NVS) Swiss stock has an average rating of hold and mean price target of CHF125.60, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","BK4588","BK4585","PPH","BK4578","LU0211331839.USD","IE0002141913.USD","IE00B4R5TH58.HKD","IE00B2B36J28.USD","LU0208291251.USD","LU0070302665.USD","IE00BFTCPJ56.SGD","MEDX","BK4532","IE0009355771.USD","LU0320765489.SGD","NVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666258492","title":"Merck & Co Inc : Leerink Partners Raises Target Price to $161 from $127","url":"https://stock-news.laohu8.com/highlight/detail?id=2666258492","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666258492?lang=en_us&edition=fundamental","pubTime":"2026-09-09 18:17","pubTimestamp":1788949066,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nFWN4510IW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GDOC","IXJ","LU1989772840.SGD","LU2023250504.SGD","LU1093756325.SGD","LU1037948897.HKD","BK4585","LU1032466523.USD","IE00BBT3K403.USD","LU0234572021.USD","LU0320765489.SGD","LU1923622614.USD","LU0124676726.USD","LU1066051225.USD","SG9999015358.SGD","LU1983299246.USD","VHT","LU1934455863.HKD","SG9999015341.SGD","BK4559","SG9999014559.SGD","IHE","LU0265550946.USD","LU2357627491.SGD","LU1989772923.USD","LU0477156953.USD","MRK","LU0006306889.USD","LU2106854487.HKD","SG9999002224.SGD","LU1934455194.USD","LU1571399168.USD","LU1917777945.USD","LU1066051498.USD","BK4550","LU2125909593.SGD","LU2023250843.SGD","LU1057294990.SGD","LU0965509101.SGD","LU2324357040.USD","IE00BJT1NW94.SGD","LU0130517989.USD","IE0009355771.USD","LU1035773651.USD","SG9999014575.USD","SGXZ57979304.SGD","SG9999001176.SGD","LU0965509010.AUD","LU0130102774.USD","LU1037948541.HKD","LU0211331839.USD","LU1066053197.SGD","TRUH","LU0070302665.USD","IE00BFTCPJ56.SGD","PPH","SG9999001176.USD","FTXH","SG9999014542.SGD","JDOC","IE00BLSP4239.USD","LU2491049909.HKD","LU1066051811.HKD","LU1201861249.SGD","LU0985320562.USD","LU2125909247.SGD","LU0980610538.SGD","LU0861579265.USD","LU2433249047.HKD","LU2089984988.USD","SG9999013999.USD","LU1934455277.USD","LU1061106388.HKD","BK4588","LU0238689110.USD","LU0098860793.USD","LU1585245621.USD","LU0265550359.USD","LU0289739699.SGD","LU1162221912.USD","LU0965508806.USD","BK4516","BK4533","BK4534","LU1941712348.USD","SG9999002232.USD","LU1929549753.HKD","LU1116320901.HKD","LU1116320737.USD","LU0058720904.USD","LU2491050071.SGD","XLV","LU1023059063.AUD","LU0266013472.USD","LU2491050154.USD","LU1291159041.SGD","LU2468319806.SGD","LU0823416689.USD","IE00BLSP4452.SGD","FHLC","LU1974910355.USD","IE0002141913.USD","LU2125154935.USD","LU2461242641.AUD","LU0106261372.USD","LU2360032135.SGD","LU2125154778.USD","LU1699723380.USD","IE00BSNM7G36.USD","RXL","LU0122379950.USD","LU1069347547.HKD","HRTS","LU0689626769.HKD","LU1093756168.USD","IE00B2B36J28.USD","IE00BN8TJ469.HKD","LU1989771016.USD","LU0965509283.SGD","LU0868494708.USD","LU2361044865.SGD","LU0942090050.USD","LU0320765646.SGD","IE000M9KFDE8.USD","LU1430594728.SGD","PAWZ","SG9999014567.USD","LU0859254822.USD","IE00B4R5TH58.HKD","LU0203347892.USD","LU0432979614.USD","LU1941712264.USD","IE00BJJMRZ35.SGD","LU2361045086.USD","LU2361044949.HKD","LU0208291251.USD","LU0648001328.SGD","LU0868494617.USD","LU2112291526.USD","IE00B1BXHZ80.USD","IYH","LU0203345920.USD","BMED","BK4007","SG9999001440.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666450584","title":"Merck price target raised to $161 from $127 at Leerink","url":"https://stock-news.laohu8.com/highlight/detail?id=2666450584","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666450584?lang=en_us&edition=fundamental","pubTime":"2026-09-09 18:10","pubTimestamp":1788948612,"startTime":"0","endTime":"0","summary":"Leerink raised the firm’s price target on Merck (MRK) to $161 from $127 and keeps an Outperform rating on the shares. Published first on TheFly – t...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/merck-price-target-raised-to-161-from-127-at-leerink-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/merck-price-target-raised-to-161-from-127-at-leerink-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0648001328.SGD","LU0130102774.USD","LU1035773651.USD","BK4559","IE000M9KFDE8.USD","LU0211331839.USD","LU2491050071.SGD","LU1974910355.USD","BMED","SG9999014559.SGD","LU2491050154.USD","LU2491049909.HKD","FTXH","IE00BN8TJ469.HKD","BK4534","LU1093756168.USD","LU2125909247.SGD","LU0965508806.USD","LU1162221912.USD","LU1057294990.SGD","SG9999014575.USD","IE00B2B36J28.USD","LU1989772923.USD","LU1037948541.HKD","IE00BBT3K403.USD","LU0058720904.USD","LU2125909593.SGD","LU1201861249.SGD","LU2089984988.USD","LU0006306889.USD","IE0002141913.USD","LU0106261372.USD","LU2023250504.SGD","LU0477156953.USD","IE00BLSP4452.SGD","BK4516","LU2106854487.HKD","IHE","LU1917777945.USD","XLV","LU0965509010.AUD","LU1983299246.USD","LU2461242641.AUD","HRTS","LU2360032135.SGD","LU0689626769.HKD","JDOC","LU2361044865.SGD","LU1032466523.USD","LU1066051225.USD","LU1929549753.HKD","LU0265550946.USD","LU2125154935.USD","LU0266013472.USD","BK4588","IE00B1BXHZ80.USD","LU2023250843.SGD","LU1069347547.HKD","LU1116320737.USD","TRUH","SG9999001176.USD","LU1923622614.USD","LU1941712264.USD","SG9999002232.USD","IE0009355771.USD","LU0985320562.USD","PAWZ","IE00BJJMRZ35.SGD","LU2361044949.HKD","IE00B4R5TH58.HKD","LU2433249047.HKD","LU0965509283.SGD","LU0965509101.SGD","LU1116320901.HKD","RXL","LU1989772840.SGD","LU1934455194.USD","SG9999015358.SGD","IE00BLSP4239.USD","LU0203345920.USD","IE00BSNM7G36.USD","BK4550","LU1989771016.USD","LU1291159041.SGD","IE00BJT1NW94.SGD","LU1699723380.USD","LU0861579265.USD","LU0432979614.USD","LU1066053197.SGD","BK4585","VHT","LU1934455277.USD","SG9999015341.SGD","LU1934455863.HKD","SG9999002224.SGD","LU1093756325.SGD","LU0868494708.USD","LU0942090050.USD","LU2357627491.SGD","FHLC","LU1061106388.HKD","LU0130517989.USD","SGXZ57979304.SGD","SG9999001440.SGD","LU0823416689.USD","SG9999001176.SGD","IXJ","LU0098860793.USD","LU0238689110.USD","LU2112291526.USD","LU1023059063.AUD","LU1585245621.USD","SG9999013999.USD","LU2361045086.USD","LU0208291251.USD","BK4007","LU0122379950.USD","SG9999014567.USD","LU1430594728.SGD","BK4533","LU0859254822.USD","LU0203347892.USD","LU2468319806.SGD","PPH","LU0234572021.USD","LU0320765489.SGD","IYH","IE00BFTCPJ56.SGD","MRK","LU1066051498.USD","LU0070302665.USD","LU0868494617.USD","LU0980610538.SGD","LU2324357040.USD","GDOC","LU1066051811.HKD","LU0265550359.USD","LU0289739699.SGD","SG9999014542.SGD","LU0124676726.USD","LU1571399168.USD","LU1941712348.USD","LU0320765646.SGD","LU2125154778.USD","LU1037948897.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666854435","title":"Novartis's Stock Selloff Looks Overdone","url":"https://stock-news.laohu8.com/highlight/detail?id=2666854435","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666854435?lang=en_us&edition=fundamental","pubTime":"2026-09-09 16:24","pubTimestamp":1788942240,"startTime":"0","endTime":"0","summary":"0823 GMT - Novartis's stock selloff on the failure of a neuromuscular drug in a clinical trial looks overdone and upcoming study results could be more positive for the Swiss drugmaker, Citi analysts say in a research note. The company reiterated its 2025-2030 outlook and trial setbacks for experimental neuromuscular and heart drugs del-desiran and pelacarsen are partially mitigated by the success of its remibrutinib medicine in a multiple sclerosis study, the analysts say. Full data for the MS study and results from another trial for the same drug in skin condition hidradenitis suppurativa could play in Novartis's favor, they add. Citi cuts its target price on Novartis stock to 135 Swiss francs from 142 francs. Shares fall 1.1% to 110.54 francs, after closing 11% lower Tuesday.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","NVS","IE00B4R5TH58.HKD","IE00BJT1NW94.SGD","PPH","IE0002141913.USD","IE0009355771.USD","LU0070302665.USD","MEDX","BK4588","BK4532","IE00BFTCPJ56.SGD","BK4007","BK4578","LU0320765489.SGD","LU0208291251.USD","IE00BJJMRZ35.SGD","IE00B2B36J28.USD","LU0211331839.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":13,"pageCount":3,"totalSize":250,"code":"91000000","status":"200"}]}}